Longeveron (LGVN) Profit After Tax Growth (3y) (2023 - 2026)
Longeveron (LGVN) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
PAT Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
33.21% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
30.60% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
16.53% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-154.28% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Longeveron |
20.35 Bn |
20.33 Bn |
264,000.00 |
-0.98% |
| Date | Value |
|---|
| Mar 31, 2026 |
-0.98% |
| Dec 31, 2025 |
-6.63% |
| Sep 30, 2025 |
-11.25% |
| Jun 30, 2025 |
3.67% |
| Mar 31, 2025 |
-12.52% |
| Dec 31, 2024 |
-0.25% |
| Sep 30, 2024 |
3.09% |
| Jun 30, 2024 |
12.01% |
| Mar 31, 2024 |
-9.64% |
| Dec 31, 2023 |
-64.17% |
| Sep 30, 2023 |
-75.91% |
| Jun 30, 2023 |
-66.69% |
| Mar 31, 2023 |
-178.48% |
